U.S. markets closed

  • S&P Futures

    4,328.25
    -9.25 (-0.21%)
     

  • Dow Futures

    33,858.00
    -34.00 (-0.10%)
     

  • Nasdaq Futures

    14,827.75
    -32.00 (-0.22%)
     

  • Russell 2000 Futures

    1,805.10
    -4.00 (-0.22%)
     

  • Crude Oil

    91.66
    -0.05 (-0.05%)
     

  • Gold

    1,881.80
    +3.20 (+0.17%)
     

  • Silver

    22.83
    +0.09 (+0.39%)
     

  • EUR/USD

    1.0573
    +0.0006 (+0.05%)
     

  • 10-Yr Bond

    4.5970
    -0.0290 (-0.63%)
     

  • Vix

    17.34
    -0.88 (-4.83%)
     

  • GBP/USD

    1.2210
    +0.0004 (+0.04%)
     

  • USD/JPY

    149.3370
    +0.0630 (+0.04%)
     

  • Bitcoin USD

    27,096.72
    +727.26 (+2.76%)
     

  • CMC Crypto 200

    581.07
    +16.28 (+2.88%)
     

  • FTSE 100

    7,601.85
    +8.63 (+0.11%)
     

  • Nikkei 225

    31,827.55
    -44.97 (-0.14%)
     

Can This Gene-Editing Stock Deliver 10X Returns?

George Budwell, The Motley Fool
·4 min read
Can This Gene-Editing Stock Deliver 10X Returns?

In almost every case, the market woefully underestimated the company's core value proposition ahead of a key inflection point. For example, CRISPR Therapeutics (NASDAQ: CRSP) has failed to earn a premium valuation despite having a diverse pipeline full of star candidates, a first-rate balance sheet, and a major partnership with Vertex Pharmaceuticals. Here, I discuss the central investing thesis for its fellow CRISPR/Cas9 gene-editing specialist, Intellia Therapeutics (NASDAQ: NTLA).

Continue reading